Post Content
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the best emerging technology stocks to invest in. On December 18, Guggenheim analyst Yatin Suneja raised the firm’s price target on ABIVAX to $175 from $150 with a Buy rating on the shares. This sentiment was posted as the firm cited its optimistic outlook for obefazimod in the 44-week maintenance readout, which is currently upcoming.
On December 15, ABIVAX reported its financial results for Q3 2025. The company generated $2.40 million in revenue, surpassing Street estimates by $1.06 million. However, there was a loss per share that totaled $1.68 in the quarter. The net loss for the nine months widened to €254.1 million, up from €136.9 million in 2024 ($297.94 million and $160.52 million respectively). The company’s financial activity reflects an intensified focus on its lead candidate, obefazimod, a first-in-class oral miR-124 enhancer.
R&D expenses rose to €133.4 million, driven by the progression of the ABTECT Phase 3 program in ulcerative colitis/UC and the ENHANCE-CD Phase 2b trial in Crohn’s disease. ABIVAX is preparing for several major milestones in 2026. Topline results from the ABTECT Maintenance Trial are expected in the second quarter of 2026, which will serve as the final clinical foundation for a planned NDA submission to the FDA in the second half of that year.
ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company that develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
While we acknowledge the potential of ABVX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.